keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/28299948/how-to-conduct-research-on-overdiagnosis-a-keynote-paper-from-the-egprn-may-2016-tel-aviv
#1
John Brodersen
Overdiagnosis is a growing problem worldwide. Overdiagnosis is the diagnosis of deviations, abnormalities, risk factors, and pathologies that in themselves would never cause symptoms (this applies only to risk factors and pathology), would never lead to morbidity, and would never be the cause of death. Overdiagnosis is often misinterpreted as overutilization or overtreatment. Overutilization, overtreatment, and overdiagnosis are interrelated but three distinct topics. Overutilization (establishment of standard practice that does not provide net benefit) does not have to lead to overdiagnosis or overtreatment, but the risk exists...
December 2017: European Journal of General Practice
https://www.readbyqxmd.com/read/28293123/pembrolizumab-in-the-treatment-of-metastatic-non-small-cell-lung-cancer-patient-selection-and-perspectives
#2
REVIEW
Ashwin Somasundaram, Timothy F Burns
Lung cancer is the leading killer of both men and women in the US, and the 5-year survival remains poor. However, the approval of checkpoint blockade immunotherapy has shifted the treatment paradigm and provides hope for improved survival. The ability of non-small-cell lung cancer (NSCLC) to evade the host immune system can be overcome by agents such as pembrolizumab (MK-3475/lambrolizumab), which is a monoclonal antibody targeting the programmed death 1 (PD-1) receptor. In early studies, treatment with pembrolizumab led to dramatic and durable responses in select patients (PD-L1+ tumors)...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28291584/clinical-safety-and-activity-of-pembrolizumab-in-patients-with-malignant-pleural-mesothelioma-keynote-028-preliminary-results-from-a-non-randomised-open-label-phase-1b-trial
#3
Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen
BACKGROUND: Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. We assessed the safety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in advanced solid tumours expressing programmed cell death ligand 1 (PD-L1) and report here on the interim analysis of the malignant pleural mesothelioma cohort. METHODS: Previously treated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 centres in six countries...
March 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28288469/individual-risk-and-prevention-of-complications-doctors-advice-to-persons-wishing-a-new-tattoo
#4
Jørgen Serup
Doctors who are consulted about health and tattoo risks have an important role in the prevention of an individual's tattoo complications. Tattooing is a tremendous exposure of the human body to needle operation, particles, and chemicals. The risk is related to a person's health condition, level of insight, decision-making, and to the operation of tattooing, tattoo inks and utensils, tattoo parlour, and the aftercare. Tattooing is painful minor surgery performed without anesthesia. It can be associated with syncope...
2017: Current Problems in Dermatology
https://www.readbyqxmd.com/read/28283736/phase-1b-study-of-pembrolizumab-mk-3475-anti-pd-1-monoclonal-antibody-in-japanese-patients-with-advanced-melanoma-keynote-041
#5
Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, Hironobu Ihn, Hiroshi Uchi, Takashi Inozume, Yoshio Kiyohara, Hisashi Uhara, Kazuhiko Nakagawa, Hiroshi Furukawa, Hidefumi Wada, Kazuo Noguchi, Takashi Shimamoto, Kenji Yokota
PURPOSE: This phase I b study evaluated the safety and anti-tumor activity of pembrolizumab in Japanese patients with advanced melanoma. METHODS: Pembrolizumab (2 mg/kg) was given every 3 weeks (Q3W) for up to 2 years or until confirmed progression or unacceptable toxicity. The tumor response was assessed as per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by both investigator review and central review. RESULTS: Forty-two patients with advanced melanoma received pembrolizumab...
March 11, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28248833/pathophysiology-of-the-gut-and-the-microbiome-in-the-host-response
#6
John D Lyons, Craig M Coopersmith
OBJECTIVE: To describe and summarize the data supporting the gut as the motor driving critical illness and multiple organ dysfunction syndrome presented at the National Institute of Child Health and Human Development MODS Workshop (March 26-27, 2015). DATA SOURCES: Summary of workshop keynote presentation. STUDY SELECTION: Not applicable. DATA EXTRACTION: Presented by an expert in the field, the data assessing the role of gastrointestinal dysfunction driving critical illness were described with a focus on identifying knowledge gaps and research priorities...
March 2017: Pediatric Critical Care Medicine
https://www.readbyqxmd.com/read/28246756/-first-line-therapy-in-advanced-renal-cell-carcinoma-a-randomized-open-label-phase%C3%A2-iii-study-evaluating-the-efficacy-and-safety-of-pembrolizumab-mk-3475-in-combination-with-axitinib-compared-to-sunitinib-monotherapy-as-first-line-treatment-for-locally-advanced
#7
https://www.readbyqxmd.com/read/28212060/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma
#8
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri, Andrea Necchi, Winald Gerritsen, Howard Gurney, David I Quinn, Stéphane Culine, Cora N Sternberg, Yabing Mai, Christian H Poehlein, Rodolfo F Perini, Dean F Bajorin
Background Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options. Methods In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy to receive pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1 [PD-1]) at a dose of 200 mg every 3 weeks or the investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine...
March 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28179673/presentations-keynote-speakers-must-try-harder
#9
Judy Ford
No abstract text is available yet for this article.
February 8, 2017: Nature
https://www.readbyqxmd.com/read/28134835/-the-24th-conference-of-the-groupement-des-pharmacochimistes-de-l-arc-atlantique-gp2a
#10
Jean-Jacques Hélesbeux, Olivier Duval
The GP2A European Conference is a two-day meeting focused on medicinal chemistry and the use of tools to explore all fields of drug discovery and drug design such as molecular modelling, bioorganic chemistry, MS studies, in vitro in vivo assays, and structure activity relationships. Abstracts of keynote lectures, plenary lectures, junior lectures, flash presentations, and posters presented during the meeting are collated in this report.
January 28, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28129007/a-new-frontier-for-targeted-therapy-in-nsclc-clinical-efficacy-of-pembrolizumab-in-the-inhibition-of-programmed-cell-death-1-pd-1
#11
Raffaele Addeo
Non-small-cell lung cancer (NSCLC) is the main pathological type among lung cancers, and it is often diagnosed at an advanced stage of the disease when it is no longer amenable to curative treatments. During recent decades, the survival rate for lung cancer patients has improved significantly in only those whose tumours harbour a driver mutation. Immune checkpoint inhibition is a promising therapeutic strategy for lung cancer. The Keynote 024 is randomized, open-label, international, phase III study to evaluate the efficacy of pembrolizumab, an antibody directed to programmed death 1 (PD-1), an immune checkpoint inhibitor, compared with platinum-based chemotherapy in patients with previously untreated advanced NSCLC and PD-L1 expression in at least 50% of the tumour cells...
March 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28125365/cost-effectiveness-of-pembrolizumab-versus-ipilimumab-in-ipilimumab-na%C3%A3-ve-patients-with-advanced-melanoma-in-the-united-states
#12
Jingshu Wang, Bartosz Chmielowski, James Pellissier, Ruifeng Xu, Kendall Stevinson, Frank Xiaoqing Liu
BACKGROUND: Recent clinical trials have shown that pembrolizumab significantly prolonged progression-free survival and overall survival compared with ipilimumab in ipilimumab-naïve patients with unresectable or metastatic melanoma. However, there has been no published evidence on the cost-effectiveness of pembrolizumab for this indication. OBJECTIVE: To assess the long-term cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naïve patients with unresectable or meta-static melanoma from a U...
February 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28077910/the-first-mediterranean-seminar-on-science-writing-editing-and-publishing-sarajevo-december-2-3-2016
#13
REVIEW
Izet Masic, Doncho Donev, Osman Sinanovic, Miro Jakovljevic, Enver Zerem, Dejan B Milosevic, Srecko Gajovic, Armen Yuri Gasparyan, Sekib Sokolovic, Nermin Salkic, Selma Uzunovic, Silva Dobric, Floreta Kurti, Edin Begic, Admir Kurtcehajic
The First Mediterranean Seminar on Science Writing, Editing & Publishing (SWEP 2016) was held in Sarajevo, Bosnia & Herzegovina from 2nd to 3rd December 2016. It was organized by Academy of Medical Sciences of Bosnia and Herzegovina, running concurrent sessions as part of its Annual Meeting titled " "Days of AMNuBiH - Theory and Practice in Science Communication and Scientometrics". Hotel Bosnia in the city centre was the chosen venue. On the first day, nineteen presentations on various issues of science writing and publication ethics were delivered by speakers from Croatia, Serbia, Macedonia, Albania, Bosnia & Herzegovina and the UK (Asim Kurjak, Milivoj Boranić, Doncho Donev, Osman Sinanović, Miro Jakovljević, Enver Zerem, Dejan Milošević, Silva Dobrić, Srećko Gajović, Izet Mašić, Armen Yuri Gasparyan, Šekib Sokolović, Nermin Salkić, Selma Uzunović, Admir Kurtčehajić, Edin Begić and Floreta Kurti)...
December 2016: Acta Informatica Medica: AIM
https://www.readbyqxmd.com/read/28052280/igics-jga-keynote-program-the-9th-international-gastrointestinal-consensus-symposium-igics-gastrointestinal-infections-february-27-2016-keio-plaza-hotel-tokyo-japan-abstracts
#14
https://www.readbyqxmd.com/read/28047831/we-f-brc-00-keynote-address-learning-from-medical-errors-a-partnership-for-progress
#15
Michael Herman, Jean Moran
Leilani Schweitzer understands medical error as few others do: through the death of her child. Faced with this profound loss, she has made a choice. Instead of pursing action through the courts she works with healthcare community to understand why mistakes happen and what can be done to respond to them in a meaningful way. In this keynote address for the TG100 Certificate Course on Risk Analysis, she will share her story and the lessons that have emerged. She will highlight the importance of investigating and understanding errors, as well as the role of leadership in accomplishing this...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047175/we-f-brc-01-keynote-address-learning-from-medical-errors-a-partnership-for-progress
#16
L Schweitzer
Leilani Schweitzer understands medical error as few others do: through the death of her child. Faced with this profound loss, she has made a choice. Instead of pursing action through the courts she works with healthcare community to understand why mistakes happen and what can be done to respond to them in a meaningful way. In this keynote address for the TG100 Certificate Course on Risk Analysis, she will share her story and the lessons that have emerged. She will highlight the importance of investigating and understanding errors, as well as the role of leadership in accomplishing this...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28033210/2016-visionary-leader-bob-dent
#17
Brandon Kit Bredimus
The following manuscript is the winning Richard Hader Visionary Leader 2016 entry submitted to Nursing Management in recognition of Dr. Bob Dent, DNP, MBA, RN, NEA-BC, CENP, FACHE, senior vice president, chief operating officer, and CNO for Midland Memorial Hospital in Midland, Tex. Dr. Dent was formally recognized for his achievements before the Keynote Address at Congress2016, November 8, in Las Vegas, Nev. There, he received the award, sponsored by Hackensack Meridian Health.
January 2017: Nursing Management
https://www.readbyqxmd.com/read/28027149/thirteenth-annual-warren-k-sinclair-keynote-address-where-are-the-radiation-professionals-warp
#18
Richard E Toohey
In July 2013, the National Council on Radiation Protection and Measurements convened a workshop for representatives from government, professional organizations, academia, and the private sector to discuss a potential shortage of radiation protection professionals in the not-too-distant future. This shortage manifests itself in declining membership of professional societies, decreasing enrollment in university programs in the radiological sciences, and perhaps most importantly, the imminent retirement of the largest birth cohort in American history, the so-called "baby boomer" generation...
February 2017: Health Physics
https://www.readbyqxmd.com/read/27998967/antibody-mediated-thyroid-dysfunction-during-t-cell-checkpoint-blockade-in-patients-with-non-small-cell-lung-cancer
#19
J C Osorio, A Ni, J E Chaft, R Pollina, M K Kasler, D Stephens, C Rodriguez, L Cambridge, H Rizvi, J D Wolchok, T Merghoub, C M Rudin, S Fish, M D Hellmann
BACKGROUND: PD-1 blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is generally well tolerated, although immune-related adverse events (irAEs) can occur. Autoimmune thyroid dysfunction is among the most common irAE, but an assessment of the clinical, mechanistic, and immunologic features have not been previously described. PATIENT AND METHODS: Patients with advanced non-small cell lung cancer (NSCLC) treated with pembrolizumab at Memorial Sloan Kettering Cancer Center (N=51) as part of KEYNOTE-001 (NCT01295827) were included...
December 19, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27957299/conference-report-international-conference-on-health-sciences-and-medical-technologies-tlemcen-algeria-27-29-september-2016-ichsmt-16
#20
Abdeldjalil Khelassi
The International Conference on Health Sciences and Medical Technologies (ICHSMT'16) was held in Tlemcen, Algeria from 27-29 September 2016. The conference was organized by the University Of Tlemcen, in partnership with Electronic Physician Journal, Mehr Publishing, and Mehrafarin Scientific Publishing. There were participants from 14 nations who presented their research in poster or oral presentations. There were also some keynote speakers who gave talks on topics such as community health, ethics of publishing medical research, and scientific writing...
October 2016: Electronic Physician
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"